Jones Day partner Maureen Bennett talks about how advancements in digital technology and their clinical trial applications have introduced additional regulatory regimes in the United States and the European Union, and describes the differences between the U.S. and EU models. Maureen also discusses the new clinical trial regulations expected from the U.S. Food and Drug Administration in the fall of 2020.
Press CTRL+C to copy embed code to clipboard
